27.06.2025 14:38 | SVNS | AGM Statement | RNS |
27.06.2025 08:54 | SVNS | Holding(s) in Company | RNS |
26.06.2025 10:21 | SVNS | Initiation of Research Coverage | Reach |
23.06.2025 11:12 | SVNS | Solvonis granted US patent for AI-led CNS compound programme | Alliance |
23.06.2025 07:00 | SVNS | Allowance of U.S. patent covering AI-supported CNS | RNS |
20.06.2025 12:02 | TEK, SUN, RKH | UK shareholder meetings calendar - next 7 days | Alliance |
11.06.2025 22:13 | SVNS, BMS, AVAP | TRADING UPDATES: Ten Lifestyle celebrates new Japan contract win | Alliance |
11.06.2025 07:30 | SVNS | Initiation of AI supported CNS drug discovery | RNS |
05.06.2025 07:00 | SVNS | Synthesis of development candidate for SVN-SDN-014 | RNS |
03.06.2025 16:30 | SVNS | Notice of Annual General Meeting | RNS |
03.06.2025 14:02 | SVNS | Solvonis promotes Professor David Nutt to chief scientific officer | Alliance |
03.06.2025 07:00 | SVNS | Appointment of Prof. David Nutt as CSO | RNS |
02.06.2025 11:58 | SVNS | Holding(s) in Company | RNS |
30.05.2025 17:00 | SVNS | Total Voting Rights | RNS |
29.05.2025 15:11 | SVNS | Holding(s) in Company | RNS |
29.05.2025 12:02 | SVNS | Holding(s) in Company | RNS |
29.05.2025 10:30 | SVNS | Holding(s) in Company | RNS |
29.05.2025 07:00 | SVNS | Presentation at Mello2025 | Reach |
28.05.2025 07:30 | SVNS | Holding(s) in Company | RNS |
28.05.2025 07:00 | SVNS | Completion of the acquisition of Awakn | RNS |
21.05.2025 15:24 | SVNS | Publication of a Prospectus | RNS |
16.05.2025 21:51 | WBI, GUN, SVNS | TRADING UPDATES: T42 IOT Tracking extends CLN repayment dates | Alliance |
16.05.2025 07:31 | SVNS | Result of placing | RNS |
15.05.2025 16:53 | SVNS | Proposed equity fundraising via ABB | RNS |
28.04.2025 11:30 | SVNS | Result of General Meeting | RNS |
23.04.2025 07:00 | SVNS | Proposed acquisition of Awakn approved | RNS |
22.04.2025 16:58 | RWA, OCDO, NXQ | UK shareholder meetings calendar - next 7 days | Alliance |
16.04.2025 14:05 | SVNS | Solvonis shares fall with "high risk" that losses will continue | Alliance |
16.04.2025 07:00 | SVNS | Final Results for the year ended 31 December 2024 | RNS |
10.04.2025 14:00 | SVNS | Posting of Circular and Notice of General Meeting | RNS |
07.04.2025 07:00 | SVNS | Holding(s) in Company | RNS |
04.04.2025 21:44 | KGH, 4GBL, ENQ | TRADING UPDATES: Knights Group seals buy; Kanabo position uncertain | Alliance |
04.04.2025 07:00 | SVNS | Engagement of PharmaVentures | RNS |
26.03.2025 13:43 | SVNS | Solvonis reports positive progress on European patent for Awakn collab | Alliance |
26.03.2025 07:00 | SVNS | Positive progress on European Patent Application | RNS |
18.03.2025 07:00 | SVNS | Update on AWKN-SDN-14 programme | RNS |
11.03.2025 09:00 | SVNS | Holding(s) in Company | RNS |
11.03.2025 07:00 | SVNS | Appointment of Non-Executive Director | RNS |
25.02.2025 07:00 | SVNS | Presentation at PharmaSynergyRx Event | Reach |
24.02.2025 12:23 | SVNS | Solvonis to buy Awakn Life Sciences for around GBP5 million | Alliance |
24.02.2025 07:00 | SVNS | Entry into an Arrangement Agreement with Awakn | RNS |
30.01.2025 12:00 | SVNS | Proactive Investors interview with Chairman | Reach |
27.01.2025 07:00 | SVNS | Update on Awakn Life Sciences’ R&D Progress | RNS |
24.01.2025 07:00 | SVNS | Investor Presentation | Reach |
21.01.2025 14:29 | SVNS | Proactive Investors interview with CEO | Reach |
21.01.2025 07:00 | SVNS | Update on FDA Pre-IND Meeting for Awakn | RNS |
15.01.2025 07:00 | SVNS | Interview with CEO | Reach |